Current therapy of myelodysplastic syndromes

Blood Reviews

Volumn 27, Issue 5, 2013, Pages 243-259

  Zeidan, Amer M ^a   Linhares, Yuliya ^b   Gore, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Azacitidine; Chemotherapy; Decitabine; Erythropoiesis stimulating agents; Hypomethylating agents; Immunosuppressive therapy; Lenalidomide; Myelodysplastic syndromes (MDS)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYPOMETHYLATING AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VIDAZ;

5Q- SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; APPLICATION SITE REACTION; BLOOD TOXICITY; COMBINATION CHEMOTHERAPY; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATIENT PREFERENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ALLOGENEIC STEM CELL TRANSPLANTATION; AZACITIDINE; CHEMOTHERAPY; DECITABINE; ERYTHROPOIESIS-STIMULATING AGENTS; HYPOMETHYLATING AGENTS; IMMUNOSUPPRESSIVE THERAPY; LENALIDOMIDE; MYELODYSPLASTIC SYNDROMES (MDS);

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84883553823     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.07.003     Document Type: Article

References (222)

1. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
2. Raza A., Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012, 12:849-859.
3. Sekeres M.A. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw 2011, 9:57-63.
4. Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012, 125:S2-S5.
5. Mukherjee S., Sekeres M.A. What's all the fuss about? Facts and figures about bone marrow failure and conditions. Curr Hematol Malig Rep 2012, 7:300-309.
6. Zeidan A., Faltas B., Douglas B.S., Gore S. Myelodysplastic syndromes: what do hospitalists need to know?. J Hosp Med 2013, 8(6):351-357.
7. Faltas B., Zeidan A., Gergis U. Myelodysplastic syndromes: towards a risk-adaptive treatment approach. Expert Rev Hematol 2013, [in press].
8. Mufti G.J., Potter V. Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology Am Soc Hematol Educ Program 2012, 49-55.
9. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
10. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
11. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
12. Zeidan A.M., Smith B.D., Komrokji R.S., Gore S.D. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med 2013, 126:e25.
13. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
14. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
15. Malcovati L., Della Porta M.G., Strupp C., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011, 96:1433-1440.
16. Garcia-Manero G., Shan J., Faderl S., et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008, 22:538-543.
17. Kantarjian H., O'Brien S., Ravandi F., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351-1361.
18. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
19. Bejar R., Stevenson K.E., Caughey B.A., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012, 30:3376-3382.
20. Mailloux A.W., Sugimori C., Komrokji R.S., et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012, 189:3198-3208.
21. van de Loosdrecht A.A., Ireland R., Kern W., et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 2013, 54:472-475.
22. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
23. Breccia M., Salaroli A., Loglisci G., Alimena G. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. Ann Hematol 2013, 92:411-412.
24. Itzykson R., Thepot S., Quesnel B., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
25. Zeidan A., Sun Z., Thomas P., Greenberg P., Juckett M., Smith M.R., et al. Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza). J Clin Oncol 2013, (suppl; abstr 7126).
26. van der Helm L.H., Alhan C., Wijermans P.W., et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011, 155:599-606.
27. Lyons R.M. Myelodysplastic syndromes: therapy and outlook. Am J Med 2012, 125:S18-S23.
28. Fenaux P., Ades L. How we treat lower risk myelodysplastic syndromes. Blood 2013, 121:4280-4286.
29. Mitchell M., Gore S., Zeidan A. Iron chelation therapy for myelodysplastic syndromes-associated iron overload: where do we stand?. Expert Rev Hematol 2013, [in press].
30. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011, 16:35-42.
31. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
32. Leitch H.A. Controversies surrounding iron chelation therapy for MDS. Blood Rev 2011, 25:17-31.
33. Goldberg S.L., Chen E., Corral M., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010, 28:2847-2852.
34. Oliva E.N., Schey C., Hutchings A.S. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res 2011, 1:160-166.
35. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., Mufti G.J. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998, 103:1075-1082.
36. Parker J.E., Mufti G.J. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998, 101:220-230.
37. Kelaidi C., Beyne-Rauzy O., Braun T., Sapena R., Cougoul P., Adès L., et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013, 92:621-631.
38. Santini V. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins. Semin Hematol 2012, 49:295-303.
39. Greenberg P.L., Attar E., Bennett J.M., et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9:30-56.
40. Jacobs A., Janowska-Wieczorek A., Caro J., Bowen D.T., Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989, 73:36-39.
41. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
42. Greenberg P.L., Sun Z., Miller K.B., et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009, 114:2393-2400.
43. Davidoff A.J., Weiss S.R., Baer M.R., et al. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res 2013, 37:675-680.
44. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
45. Golshayan A.R., Jin T., Maciejewski J., et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007, 137:125-132.
46. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
47. Gabrilove J., Paquette R., Lyons R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142:379-393.
48. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046.
49. Davidoff A.J., Weiss Smith S., Baer M.R., et al. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica 2012, 97:128-132.
50. Negrin R.S., Stein R., Doherty K., et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87:4076-4081.
51. Smith S.W., Sato M., Gore S.D., et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012, 97:15-20.
52. Van den Berghe H., Cassiman J.J., David G., Fryns J.P., Michaux J.L., Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974, 251:437-438.
53. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
54. Steensma D.P. Historical perspectives on myelodysplastic syndromes. Leuk Res 2012, 36:1441-1452.
55. Kantarjian H., O'Brien S., Ravandi F., et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 2009, 115:5202-5209.
56. Padron E., Komrokji R., List A.F. Biology and treatment of the 5q- syndrome. Expert Rev Hematol 2011, 4:61-69.
57. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
58. Bejar R., Tiu R., Sekeres M., Komrokji R. Myelodysplastic syndromes. Am Soc Clin Oncol Educ Book 2013, 256-270.
59. Dutt S., Narla A., Lin K., et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011, 117:2567-2576.
60. Fuchs O. Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway. Leuk Res Treat 2012, [2012;2012:179402, Electronic publication ahead of print 2012 Feb 13.]. 10.1155/2012/179402.
61. Heise C., Carter T., Schafer P., Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010, 10:1663-1672.
62. Kumar M.S., Narla A., Nonami A., et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011, 118:4666-4673.
63. Komrokji R.S., List A.F. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des 2012, 18:3198-3203.
64. Germing U., Lauseker M., Hildebrandt B., et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012, 26:1286-1292.
65. Jadersten M., Saft L., Smith A., et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011, 29:1971-1979.
66. Sebaa A., Ades L., Baran-Marzack F., et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 2012, 51:1086-1092.
67. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
68. Fenaux P., Giagounidis A., Selleslag D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118:3765-3776.
69. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86-93.
70. Sekeres M.A. Lenalidomide in MDS: 4th time's a charm. Blood 2011, 118:3757-3758.
71. Ades L., Le Bras F., Sebert M., et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 2012, 97:213-218.
72. Kuendgen A., Lauseker M., List A.F., et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2013, 27:1072-1079.
73. Gohring G., Giagounidis A., Busche G., et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010, 89:365-374.
74. Sibon D., Cannas G., Baracco F., et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 2012, 156:619-625.
75. Sekeres M.A., Maciejewski J.P., Giagounidis A.A., et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008, 26:5943-5949.
76. Ebert B.L., Galili N., Tamayo P., et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008, 5:e35.
77. Sardnal V., Rouquette A., Kaltenbach S., et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia 2013, 27(7):1610-1613.
78. Ades L., Boehrer S., Prebet T., et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009, 113:3947-3952.
79. Ades L., Fenaux P. Immunomodulating drugs in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2011, 556-560.
80. Mollgard L., Saft L., Treppendahl M.B., et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica 2011, 96:963-971.
81. Padron E., Komrokji R., List A.F. The 5q- syndrome: biology and treatment. Curr Treat Options Oncol 2011, 12:354-368.
82. Wei S., Chen X., Rocha K., et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009, 106:12974-12979.
83. Oliva E.N., Cuzzola M., Nobile F., et al. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 2010, 85:231-235.
84. Komrokji R.S., List A.F. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am 2010, 24:377-388.
85. Wei S., Chen X., McGraw K., et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2013, 32:1110-1120.
86. Zandberg D.P., Hendrick F., Vannorsdall E., et al. Tertiary center referral patterns for myelodysplastic syndrome patients are indicative of age and race disparities: a single-institution experience. Leuk Lymphoma 2012, 54:304-309.
87. Wu L., Li X., Xu F., Zhang Z., Chang C., He Q. Low RPS14 expression in MDS without 5q-aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients. Eur J Haematol 2013, 90:486-493.
88. Sekeres M.A., Gundacker H., Lancet J., et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011, 118:523-528.
89. Voutsadakis I.A., Cairoli A. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q-myelodysplastic syndromes. Leuk Lymphoma 2012, 53:779-788.
90. Caceres G., Johnson J., McGraw K., et al. Targeted repression of TP53 promotes erythropoiesis in Del(5q) MDS and overcomes clinical resistance to lenalidomide. ASH Ann Meet Abstr 2012, 120:920.
91. List A.F. New therapeutics for myelodysplastic syndromes. Leuk Res 2012, 36:1470-1474.
92. Giannouli S., Kanellopoulou T., Voulgarelis M. Myelodysplasia and autoimmunity. Curr Opin Rheumatol 2012, 24:97-102.
93. Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
94. Kordasti S.Y., Afzali B., Lim Z., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
95. Kordasti S.Y., Ingram W., Hayden J., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
96. Fozza C., Longu F., Contini S., et al. Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells. Acta Haematol 2012, 128:178-182.
97. Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009, 94:449-451.
98. Parikh A.R., Olnes M.J., Barrett A.J. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol 2012, 49:304-311.
99. Sloand E.M., Melenhorst J.J., Tucker Z.C., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
100. Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
101. Dixit A., Chatterjee T., Mishra P., et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hematol 2005, 84:565-568.
102. Chen S., Jiang B., Da W., Gong M., Guan M. Treatment of myelodysplastic syndrome with cyclosporin A. Int J Hematol 2007, 85:11-17.
103. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
104. Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
105. Passweg J.R., Giagounidis A.A., Simcock M., et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/9. J Clin Oncol 2011, 29:303-309.
106. Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003, 17:2101-2106.
107. Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
108. Sloand E.M., Olnes M.J., Shenoy A., et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010, 28:5166-5173.
109. Scott B.L., Ramakrishnan A., Fosdal M., et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol 2010, 149:706-710.
110. Platzbecker U., Haase M., Herbst R., et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005, 128:625-630.
111. Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
112. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025-3027.
113. Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.
114. Vigna E., Recchia A.G., Madeo A., et al. Epigenetic regulation in myelodysplastic syndromes: implications for therapy. Expert Opin Investig Drugs 2011, 20:465-493.
115. Aimiuwu J., Wang H., Chen P., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012, 119:5229-5238.
116. Griffiths E.A., Gore S.D. DNA methyltransferase inhibitors: class effect or unique agents?. Leuk Lymphoma 2008, 49:650-651.
117. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
118. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
119. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
120. Lubbert M., Suciu S., Baila L., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29:1987-1996.
121. Gore S.D. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2011, 550-555.
122. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
123. Fenaux P., Gattermann N., Seymour J.F., et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010, 149:244-249.
124. Steensma D.P., Stone R.M. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24:389-406.
125. Fenaux P., Bowen D., Gattermann N., et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010, 34:1410-1416.
126. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
127. Silverman L.R., Fenaux P., Mufti G.J., et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011, 117:2697-2702.
128. Gore S.D., Fenaux P., Santini V., et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013, 98(7):1067-1072.
129. Zeidan A., Gore S. Management of high-risk myelodysplastic syndrome. Myelodysplastic syndromes 2013, Springer, [in press]. 2nd edition. H.J. Deeg (Ed.).
130. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
131. Garcia-Manero G., Gore S.D., Cogle C., et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011, 29:2521-2527.
132. Itzykson R., Kosmider O., Cluzeau T., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25:1147-1152.
133. Breccia M., Loglisci G., Cannella L., et al. Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. Leuk Lymphoma 2012, 53:985-986.
134. Itzykson R., Thepot S., Quesnel B., et al. Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. Blood 2012, 119:6172-6173.
135. Estey E.H. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 2013, [Electronic publication ahead of print].
136. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
137. Steensma D.P., Baer M.R., Slack J.L., et al. Multicenter study of decitabine administered daily for 5days every 4weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009, 27:3842-3848.
138. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28:605-613.
139. Santini V., Fenaux P., Mufti G.J., et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010, 85:130-138.
140. Saunthararajah Y., Hillery C.A., Lavelle D., et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003, 102:3865-3870.
141. Garcia-Manero G., Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011, 29:516-523.
142. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
143. Prebet T., Gore S.D., Thepot S., et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012, 157(6):764-766.
144. Jabbour E., Garcia-Manero G., Batty N., et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010, 116:3830-3834.
145. Kadia T.M., Jabbour E., Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011, 38:682-692.
146. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
147. Oosterveld M., Muus P., Suciu S., et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002, 16:1615-1621.
148. Wattel E., De Botton S., Luc Lai J., et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997, 98:983-991.
149. Beran M., Shen Y., Kantarjian H., et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001, 92:1999-2015.
150. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011, 86:490-498.
151. Kantarjian H., Beran M., Cortes J., et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006, 106:1099-1109.
152. Knipp S., Hildebrand B., Kundgen A., et al. Intensive chemotherapy is not recommended for patients aged >60years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007, 110:345-352.
153. Bello C., Yu D., Komrokji R.S., et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011, 117:1463-1469.
154. Platzbecker U. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes. Semin Hematol 2012, 49:342-349.
155. Zeidan A., Gore S., Komrokji R. Higher-risk myelodysplastic syndromes with del5q: Is sequential azacitidine-lenalidomide combination the way to go?. Expert Rev Hematol 2013, 6(3):251-254.
156. Griffiths E.A., Gore S.D. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008, 45:23-30.
157. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 2003, 4:13-18.
158. Prebet T., Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011, 20:287-295.
159. Cashen A., Juckett M., Jumonville A., et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012, 91:33-38.
160. Dimicoli S., Jabbour E., Borthakur G., et al. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol 2012, 87:127-129.
161. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
162. Yang H., Hoshino K., Sanchez-Gonzalez B., Kantarjian H., Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 2005, 29:739-748.
163. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
164. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
165. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361-6369.
166. Prebet T., Gore S., Sun Z., et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. ASH Annu Meet Abstr 2010, 116:601.
167. Sekeres M.A., List A.F., Cuthbertson D., et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010, 28:2253-2258.
168. Sekeres M.A., Tiu R.V., Komrokji R., et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012, 120:4945-4951.
169. Platzbecker U., Braulke F., Kundgen A., et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 2013, 27(6):1403-1407.
170. Borthakur G., Huang X., Kantarjian H., et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 2010, 51:73-78.
171. Bayraktar U.D., Domingo G.C., Schmit J., Pereira D. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2011, 52:913-915.
172. Nand S., Godwin J., Smith S., et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008, 49:2141-2147.
173. Komrokji R.S., Lancet J.E., Swern A.S., et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012, 120:3419-3424.
174. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010, 28:405-411.
175. Giralt S.A., Horowitz M., Weisdorf D., Cutler C. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol 2011, 29:566-572.
176. Xu F., Deeg H.J. Current status of allogeneic hematopoietic cell transplantation for MDS. Curr Pharm Des 2012, 18:3215-3221.
177. Giralt S. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Curr Hematol Rep 2005, 4:200-207.
178. Koreth J., Pidala J., Perez W.S., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013, 31(21):2662-2670.
179. Platzbecker U., Schetelig J., Finke J., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012, 18:1415-1421.
180. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
181. Appelbaum F.R. The role of hematopoietic cell transplantation as therapy for myelodysplasia. Best Pract Res Clin Haematol 2011, 24:541-547.
182. Cutler C. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2010, 325-329.
183. Cutler C. Patient selection for transplantation in the myelodysplastic syndromes. Hematol Oncol Clin North Am 2010, 24:469-476.
184. Gyurkocza B., Deeg H.J. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?. Blood Rev 2012, 26:247-254.
185. Armand P., Kim H.T., Rhodes J., et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:852-860.
186. Cutler C. Transplantation for MDS in the elderly: more evidence, or more bias?. Biol Blood Marrow Transplant 2012, 18:1320-1321.
187. Deeg H.J., Bartenstein M. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. Arch Immunol Ther Exp (Warsz) 2012, 60:31-41.
188. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
189. Deeg H.J., Scott B.L., Fang M., et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012, 120:1398-1408.
190. Della Porta M.G., Malcovati L., Strupp C., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
191. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 25:4246-4254.
192. Zipperer E., Pelz D., Nachtkamp K., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009, 94:729-732.
193. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
194. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
195. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
196. Lee J.H., Lee J.H., Lim S.N., et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant 2010, 45:450-457.
197. Faderl S., Garcia-Manero G., Estrov Z., et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010, 28:2755-2760.
198. Faderl S., Garcia-Manero G., Jabbour E., et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012, 118:722-728.
199. Reddy M.V., Venkatapuram P., Mallireddigari M.R., et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 2011, 54:6254-6276.
200. Kantarjian H., Garcia-Manero G., O'Brien S., et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 2010, 28:285-291.
201. Fenaux P., Raza A., Mufti G.J., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007, 109:4158-4163.
202. Itzykson R., Fenaux P. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol 2009, 16:77-83.
203. Jabbour E., Kantarjian H., Ravandi F., et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2011, 117:1236-1244.
204. Schiller G.J., Slack J., Hainsworth J.D., et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006, 24:2456-2464.
205. Vey N., Bosly A., Guerci A., et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006, 24:2465-2471.
206. Duong V.H., Jaglal M.V., Zhang L., et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res 2013, 37:300-304.
207. Raza A., Galili N., Smith S., et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009, 113:6533-6540.
208. Raza A., Galili N., Mulford D., et al. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol 2012, 5. [18-8722-5-18].
209. Sekeres M.A., Kantarjian H., Fenaux P., et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011, 117:992-1000.
210. Oliva E.N., Santini V., Zini G., et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS). ASH Ann Meet Abstr 2012, 120:923.
211. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005, 11:312-319.
212. Muller A.J., Malachowski W.P., Prendergast G.C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 2005, 9:831-849.
213. Ustun C., Miller J.S., Munn D.H., Weisdorf D.J., Blazar B.R. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood 2011, 118:5084-5095.
214. Zhou L., McMahon C., Bhagat T., et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res 2011, 71:955-963.
215. Zhou L., Nguyen A.N., Sohal D., et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008, 112:3434-3443.
216. Raje N., Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010, 12:586-597.
217. Lowenberg B., Morgan G., Ossenkoppele G.J., et al. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 2010, 28:4333-4338.
218. Navas T., Zhou L., Estes M., et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma 2008, 49:1963-1975.
219. Navas T.A., Mohindru M., Estes M., et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006, 108:4170-4177.
220. Sokol L., Cripe L., Kantarjian H., et al. Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 2013, 27:977-980.
221. Sun S., Schiller J.H., Spinola M., Minna J.D. New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117:2740-2750.
222. Jamieson C., Cortes J., Oehler V., et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. ASH Ann Meet Abstr 2011, 118:424.